Central Nervous System News and Research

RSS

Gestational diabetes along with poverty raises risk of ADHD in the child: Study

According to a new study pregnant mothers with gestational diabetes are more likely to have kids with attention deficit hyperactivity disorder. Additionally if they have a poorer socioeconomic status, the child is 14 times more likely to be diagnosed with the behavioral disorder, researchers at Queens College and Mount Sinai School of Medicine found.

3 Jan 2012

InSightec completes enrollment in ExAblate Neuro clinical study for Essential Tremor

InSightec Ltd, the global leader in MR guided Focused Ultrasound therapy, announced today that it has completed enrollment in the world's first feasibility study evaluating the use of MRgFUS for treatment of Essential Tremor, using ExAblate Neuro at University of Virginia, Charlottesville, Virginia.

3 Jan 2012

Lundbeck invests in Ossianix to focus on biotherapeutics for CNS disorders

Ossianix, Inc. today announced a strategic investment by H. Lundbeck A/S in the form of a Convertible Promissory Note. The proceeds from Lundbeck's investment is expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing Ossianix's proprietary single domain antibody platform modeled on the shark vNAR structure.

3 Jan 2012

NCC announces grant recipients of Childhood Cancer Research Coalition program

The National Cancer Coalition (NCC) is pleased to announce research grant recipients.

26 Dec 2011

Faulty lipid metabolism may cause MS, says forensic anthropologist

An article to be published in the December 2011 issue of The Quarterly Review of Biology argues that multiple sclerosis, long viewed as primarily an autoimmune disease, is not actually a disease of the immune system.

23 Dec 2011

New way to awaken paternal Ube3a allele linked with Angelman syndrome

Results of a new study from the University of North Carolina at Chapel Hill may help pave the way to a treatment for a neurogenetic disorder often misdiagnosed as cerebral palsy or autism.

22 Dec 2011

BMDCs can contribute to olfactory neurons through plasticity mechanism

Bone marrow-derived stem cells (BMDCs) have been recognized as a source for transplantation because they can contribute to different cell populations in a variety of organs under both normal and pathological conditions.

20 Dec 2011

Alkermes commences ALKS 9070 phase 3 clinical trial for schizophrenia

Alkermes plc today announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia. ALKS 9070, a proprietary Alkermes molecule, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY for the treatment of a number of central nervous system disorders.

19 Dec 2011

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

Nektar Therapeutics today announced positive data from a Phase 1 clinical study of NKTR-181 evaluating multiple ascending oral doses of NKTR-181 over an 8-day treatment period in healthy subjects.

14 Dec 2011

New study: Insulin signaling is altered in human pancreas

Insulin signaling is altered in the pancreas, a new study shows for the first time in humans. The errant signals disrupt both the number and quality of beta cells - the cells that produce insulin.

14 Dec 2011

Researchers convert astrocytes directly into dopamine-producing neurons

In efforts to find new treatments for Parkinson's Disease (PD), researchers from the Perelman School of Medicine at the University of Pennsylvania have directly reprogrammed astrocytes, the most plentiful cell type in the central nervous system, into dopamine-producing neurons.

14 Dec 2011

Matrix protein tenascin C regulates astrocyte development

How astrocytes, certain cells of the nervous system, are generated was largely unknown up to now. Bochum's researchers have now investigated what influence the cell environment, known as the extracellular matrix, has on this process.

13 Dec 2011

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Reata, Abbott partner to develop and commercialize AIMs for chronic diseases

Abbott and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators.

12 Dec 2011

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma.

12 Dec 2011

People in Northern Ireland less likely to develop cancers

People in Northern Ireland have a lower risk of developing some cancers than those living in the Republic of Ireland, according to the All-Ireland Cancer Atlas - a collaborative publication by the Northern Ireland Cancer Registry at Queen's University Belfast and the National Cancer Registry in Cork.

12 Dec 2011

Young football players may be at higher risk for stroke

Young football players may be at higher risk for stroke, according to a new study released in Journal of Child Neurology (JCN), published by SAGE.

9 Dec 2011

Intensive maternal care during infancy promotes effect of NPY in brain

Neuropeptide Y (NPY) is the most abundant peptide hormone of the central nervous system. It is involved in various processes including stress management, the development of anxiety behaviour and body weight regulation. A collaborative research group including scientists from the Max Planck Institute for Medical Research in Heidelberg has demonstrated using mice that intensive maternal care during infancy promotes the effect of NPY in the brain.

8 Dec 2011

UCSF resident to receive 2012 William P. Van Wagenen Fellowship

The William P. Van Wagenen Fellowship Selection Committee has announced Matthew Christopher Tate, MD, as the recipient of the 2012 William P. Van Wagenen Fellowship. Dr. Tate, a resident in neurological surgery at University of California in San Francisco, will commence the fellowship on July 1, 2012.

7 Dec 2011

WSU study to improve diagnosis of fetal alcohol spectrum disorders

Fetal alcohol spectrum disorders (FASDs) are one of the most common causes of birth defects worldwide and are particularly prevalent in some South African communities where heavy drinking during pregnancy is a major public health issue, particularly in the wine-growing areas of the Western Cape.

6 Dec 2011